SOXS Optical Design

The report describes the optical design of the Son Of X-Shooter (SOXS) intrument for the NTT ESO telescope, presented at the instrument Optical FD

SOXS: a wide band spectrograph to follow up transients

SOXS (Son Of X-Shooter) will be a spectrograph for the ESO NTT telescope capable to cover the optical and NIR bands, based on the heritage of the X-Shooter at the ESO-VLT. SOXS will be built and run by an international consortium, carrying out rapid and longer term Target of Opportunity requests on a variety of astronomical objects. SOXS will observe all kind of transient and variable sources from different surveys. These will be a mixture of fast alerts (e.g. gamma-ray bursts, gravitational waves, neutrino events), mid-term alerts (e.g. supernovae, X-ray transients), fixed time events (e.g. close-by passage of minor bodies). While the focus is on transients and variables, still there is a wide range of other astrophysical targets and science topics that will benefit from SOXS. The design foresees a spectrograph with a Resolution-Slit product ~ 4500, capable of simultaneously observing over the entire band the complete spectral range from the U- to the H-band. The limiting magnitude of R~20 (1 hr at S/N~10) is suited to study transients identified from on-going imaging surveys. Light imaging capabilities in the optical band (grizy) are also envisaged to allow for multi-band photometry of the faintest transients. This paper outlines the status of the project, now in Final Design Phase.Comment: 12 pages, 14 figures, to be published in SPIE Proceedings 1070

Son of X--Shooter: a multi--band instrument for a multi--band universe

Son Of X-Shooter (SOXS) will be a new instrument designed to be mounted at the Nasmyth--A focus of the ESO 3.5 m New Technology Telescope in La Silla site (Chile). SOXS is composed of two high-efficiency spectrographs with a resolution slit product 4500, working in the visible (350 -- 850 nm) and NIR (800 -- 2000 nm) range respectively, and a light imager in the visible (the acquisition camera usable also for scientific purposes). The science case is very broad, it ranges from moving minor bodies in the solar system, to bursting young stellar objects, cataclysmic variables and X-ray binary transients in our Galaxy, supernovae and tidal disruption events in the local Universe, up to gamma-ray bursts in the very distant and young Universe, basically encompassing all distance scales and astronomy branches. At the moment, the instrument passed the Preliminary Design Review by ESO (July 2017) and the Final Design (with FDR in July 2018).Comment: 23 pages, 10 Figures, accepted to be published in Frontier Research in Astrophysics 2018 Conference proceedings in Proceeding of Science. arXiv admin note: text overlap with arXiv:1807.0882

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Frontier Research in Astrophysics – III (FRAPWS2018) - Ongoing Experiments

Son Of X-Shooter (SOXS) will be a new instrument designed to be mounted at the Nasmyth–A focus of the ESO 3.5 m New Technology Telescope in La Silla site (Chile). SOXS is composed of two high-efficiency spectrographs with a resolution slit product 4500, working in the visible (350 – 850 nm) and NIR (800 – 2000 nm) range respectively, and a light imager in the visible (the acquisition camera usable also for scientific purposes). The science case is very broad, it ranges from moving minor bodies in the solar system, to bursting young stellar objects, cataclysmic variables and X-ray binary transients in our Galaxy, supernovae and tidal disruption events in the local Universe, up to gamma-ray bursts in the very distant and young Universe, basically encompassing all distance scales and astronomy branches. At the moment, the instrument passed the Preliminary Design Review by ESO (July 2017) and the Final Design (with FDR in July 2018).</p

Proceedings Volume 10707, Software and Cyberinfrastructure for Astronomy V;

SOXS (Son Of X-Shooter) is a unique spectroscopic facility that will operate at the ESO New Technology Telescope (NTT) in La Silla from 2021 onward. The spectrograph will be able to cover simultaneously the UV-VIS and NIR bands exploiting two different arms and a Common Path feeding system. We present the design of the SOXS instrument control electronics. The electronics controls all the movements, alarms, cabinet temperatures, and electric interlocks of the instrument. We describe the main design concept. We decided to follow the ESO electronic design guidelines to minimize project time and risks and to simplify system maintenance. The design envisages Commercial Off-The-Shelf (COTS) industrial components (e.g. Beckhoff PLC and EtherCAT fieldbus modules) to obtain a modular design and to increase the overall reliability and maintainability. Preassembled industrial motorized stages are adopted allowing for high precision assembly standards and a high reliability. The electronics is kept off-board whenever possible to reduce thermal issues and instrument weight and to increase the accessibility for maintenance purpose. The instrument project went through the Preliminary Design Review in 2017 and is currently in Final Design Phase (with FDR in July 2018). This paper outlines the status of the work and is part of a series of contributions describing the SOXS design and properties after the instrument Preliminary Design Review.</p

The SOXS data-reduction pipeline

The SOXS is a dual-arm spectrograph (UV-VIS & NIR) and AC due to mounted on the ESO 3.6m NTT in La Silla. Designed to simultaneously cover the optical and NIR wavelength range from 350-2050 nm, the instrument will be dedicated to the study of transient and variable events with many Target of Opportunity requests expected. The goal of the SOXS Data Reduction pipeline is to use calibration data to remove all instrument signatures from the SOXS scientific data frames for each of the supported instrument modes, convert this data into physical units and deliver them with their associated error bars to the ESO SAF as Phase 3 compliant science data products, all within 30 minutes. The primary reduced product will be a detrended, wavelength and flux calibrated, telluric corrected 1D spectrum with UV-VIS + NIR arms stitched together. The pipeline will also generate QC metrics to monitor telescope, instrument and detector health. The pipeline is written in Python 3 and has been built with an agile development philosophy that includes adaptive planning and evolutionary development. The pipeline is to be used by the SOXS consortium and the general user community that may want to perform tailored processing of SOXS data. Test driven development has been used throughout the build using `extreme' mock data. We aim for the pipeline to be easy to install and extensively and clearly documented.Comment: 15 pages, 11 figures. SPIE 202

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)